Publicaciones en colaboración con investigadores/as de University of Manchester (96)

2024

  1. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

    Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

2022

  1. Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study

    Clinical Lung Cancer, Vol. 23, Núm. 8, pp. 720-730

  2. The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report

    ESMO Open, Vol. 7, Núm. 5

2021

  1. Algorithmic assessment of cellular senescence in experimental and clinical specimens

    Nature Protocols, Vol. 16, Núm. 5, pp. 2471-2498

  2. Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

    Journal of Thoracic Oncology, Vol. 16, Núm. 12, pp. 2091-2108

  3. Physiological hypoxia restrains the senescence-associated secretory phenotype via AMPK-mediated mTOR suppression

    Molecular Cell, Vol. 81, Núm. 9, pp. 2041-2052.e6

2020

  1. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

    Journal of Clinical Oncology

  2. Line blot immunoassays in idiopathic inflammatory myopathies: Retrospective review of diagnostic accuracy and factors predicting true positive results

    BMC Rheumatology, Vol. 4, Núm. 1

2019

  1. Association analyses identify 31 new risk loci for colorectal cancer susceptibility

    Nature Communications, Vol. 10, Núm. 1

  2. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

  3. Including myositis-specific autoantibodies improves performance of the idiopathic inflammatory myopathies classification criteria

    Rheumatology (United Kingdom)

  4. Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature

    Reumatologia Clinica, Vol. 15, Núm. 1, pp. 34-42

2018

  1. Progress of the attractiveness of Rheumatology among medical speciality training candidates (MIR) in Spain

    Reumatologia Clinica, Vol. 14, Núm. 3, pp. 150-154

  2. Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: Results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

    Rheumatology (United Kingdom), Vol. 57, Núm. 9, pp. 1533-1540

2016

  1. Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies

    Arthritis and Rheumatology, Vol. 68, Núm. 9, pp. 2338-2344

  2. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

  4. HLA–DRB1 Amino Acid Positions 11/13, 71, and 74 Are Associated With Inflammation Level, Disease Activity, and the Health Assessment Questionnaire Score in Patients With Inflammatory Polyarthritis

    Arthritis and Rheumatology, Vol. 68, Núm. 11, pp. 2618-2628

  5. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: Results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis

    Rheumatology (United Kingdom), Vol. 55, Núm. 11, pp. 2033-2039